Orthocell Limited (ASX:OCC) Gains Thai FDA Approval for Remplir™
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
Category: Healthcare
ResMed Inc. (ASX:RMD) Reports Q1 2025 Financial Results
ResMed Inc. (ASX:RMD) reports Q1 2025 revenues up 8% and diluted EPS of $2.48, declaring a $0.53 dividend per share.
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Cynata Therapeutics Limited (ASX:CYP) Releases Q1 2025 Activity Report
Cynata Therapeutics (ASX:CYP) reports progress in key clinical trials and maintains a strong financial position in Q1 2025.
Atomo Diagnostics Limited (ASX:AT1) Completes $3.1M Capital Raise and Board Restructure
Atomo Diagnostics Limited (ASX:AT1) completes a $3.1 million capital raise and announces a board restructure to enhance operational efficiency and drive growth.
Proteomics International Laboratories Ltd (ASX:PIQ) Launches PromarkerD and Raises $4.5m
Proteomics International (ASX:PIQ) launches PromarkerD test in Australia and secures $4.5m funding to support its precision diagnostics growth.
Lumos Diagnostics (ASX:LDX) Secures Additional Medicare Coverage
Lumos Diagnostics (ASX:LDX) expands Medicare reimbursement for FebriDx to over 55% of US coverage, enhancing market access.
Telix Pharmaceuticals Limited (ASX:TLX) Reports $186M Q1 Revenue
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Clarity Pharmaceuticals (ASX:CU6) Signs Copper-64 Supply Agreement with Nusano
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant improvements in anxiety scores.